October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present primary endpoint and 6-month data from its DESyne BDS Plus Randomized Clinical Trial (RCT), a prospec

October 10, 2023 — The recipients of two prestigious awards — the Career Achievement Award and the TCT Geoffrey O. Hartzler Master Operator Award — have been announced by the Cardiovascular Research Foundation (CRF) ahead of its annual scientific symposium, the Transcatheter Cardiovascular Therapeutics (TCT) conference.


The global incidence of non-communicable diseases (NCDs) is currently around 40 million cases a year. Of that total, cardiovascular disease amounts to 18 million cases, with approximately 6.5 million being strokes. At 9.3 million cases per year, cancer is only slightly more prevalent.


October 9, 2023 — The vast majority of people who have a minimally invasive heart valve replacement procedure do not participate in recommended cardiac rehabilitation, a Michigan Medicine-led study finds.

October 9, 2023 — Rejuvenate Bio announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key disease-mediating pathways.

October 9, 2023 — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), announced it has received Investigational Device Exempt

October 6, 2023 —  Rady Children’s Hospital-San Diego, the largest children’s hospital on the West Coast and one of the nation’s top pediatric health care systems, and the University of California, San Diego (UCSD) are pleased to announce that Adel Younoszai, MD, has been appointed as Rady Children’s Hospital Co-Director of the Heart Institute, and Division Chief of Cardiology, Department of Pediatrics, UC San Diego. Dr.

October 6, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,1 announced new data from a Biosense Webster funded study which sought to compare the risk of heart failure incidence among atrial fibrillation (AFib) patients treated with catheter ablation versus antiarrhythmic drugs (AAD).

Subscribe Now